Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a dose-escalation study of ensovibep in symptomatic mild COVID-19
NL-OMON50810Phase 2Active, not recruiting
- Sponsor
- Molecular Partners AG
- Start
- Apr 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ensovibep in coronavirus disease 2019 (COVID-19) (2 cohorts), sponsored by Molecular Partners AG. Primary endpoints: Change in viral load and viral culture over time, Duration to PCR negativity and 1 more. Started Apr 2021; status: active, not recruiting.
02
Drugs
ensovibep
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON50810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50810.